Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications
Marta Bajeli, Antonio Corsello, Simone Foti Randazzese, Alessia Marseglia, Paola D’Agostino, Carlo Maria Rossi, Gian Luigi Marseglia, Amelia Licari · 2026
Read Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications by Marta Bajeli, Antonio Corsello, Simone Foti Randazzese, Alessia Marseglia, Paola D’Agostino, Carlo Maria Rossi, Gian Luigi Marseglia, Amelia Licari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13552420.txt.
Description
Marta Bajeli and co-authors review, in a 2026 paper, a drug for grave eosinophilic asthma in children and teens. That asthma form brings oft attacks, poor life quality, much care use, and harm from steroid loads. The drug, mepolizumab, is a made antibody that blocks interleukin-5, a signal that feeds the white cells in the ill's name. It is cleared as an add-on for kids aged six and up. Trials and real-world reads show deep, long drops in those blood cells. Grave attacks fall in a steady way across the reads.
Steroid loads can ease, and care use can drop in picked kids. Lung work and day signs gain less steadily. Harm reads look kind so far, but long child data stay thin.
Catalog record
| CREATOR | Marta Bajeli, Antonio Corsello, Simone Foti Randazzese, Alessia Marseglia, Paola D’Agostino, Carlo Maria Rossi, Gian Luigi Marseglia, Amelia Licari |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |